1. Medtech Insight
  2. >>Business

M&A Analysis: November Deal Making Hits Whole New Low

 
• By Catherine Longworth

M&A deal activity dropped dramatically in November with a mere six deals in the medtech industry, making November the weakest month of the year so far. The biggest deal of the month recorded was Edward Lifesciences $690m acquisition of Israeli start-up Valtech.

Merging Business Network-Business leaders in global agreement
November Saw M&A Deal Making Hitting Its Lowest Point For The Year So Far • Source: Shutterstock

Medtech mergers and acquisition activity hit its lowest point for the year in November with only six deals recorded on Medtech Insight'sM&A Tracker – significantly lower than the previous months and a sharp drop from the 19 deals carried out in November 2015.

While September's surge of activity had sparked hopes of a Q4 turnaround, November saw M&A activity wane considerably from October's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

BD Sees $90M Tariff Hit In Q4; 2026 Impact Reduced To $275M

 
• By Shubham Singh

BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.

Roche Eyes 2026 FDA Nod After CE Mark For pTau181 Test To Boost Global Alzheimer’s Diagnosis

 
• By Shubham Singh

The Elecsys pTau181 test, which requires only a blood sample, provides a less invasive alternative to cerebral spinal fluid procedures. A negative result could rule out Alzheimer’s and help patients avoid further testing with CSF or PET scans.